Regulation of lipocalin-2 gene by the cancer chemopreventive retinoid 4-HPR
Stefano Caramuta
Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
IFOM, FIRC Institute of Molecular Oncology, Milan, Italy
Search for more papers by this authorLoris De Cecco
Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
IFOM, FIRC Institute of Molecular Oncology, Milan, Italy
Search for more papers by this authorJames F. Reid
Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
IFOM, FIRC Institute of Molecular Oncology, Milan, Italy
Search for more papers by this authorLaura Zannini
Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
Search for more papers by this authorManuela Gariboldi
Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
IFOM, FIRC Institute of Molecular Oncology, Milan, Italy
Search for more papers by this authorLars Kjeldsen
Department of Hematology, National University Hospital, Copenhagen, Denmark
Search for more papers by this authorCorresponding Author
Marco A. Pierotti
Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
IFOM, FIRC Institute of Molecular Oncology, Milan, Italy
Department of Experimental Oncology, Istituto Nazionale Tumori, Via G Venezian 1, 20133 Milan, ItalySearch for more papers by this authorCorresponding Author
Domenico Delia
Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
Department of Experimental Oncology, Istituto Nazionale Tumori, Via G Venezian 1, 20133 Milan, ItalySearch for more papers by this authorStefano Caramuta
Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
IFOM, FIRC Institute of Molecular Oncology, Milan, Italy
Search for more papers by this authorLoris De Cecco
Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
IFOM, FIRC Institute of Molecular Oncology, Milan, Italy
Search for more papers by this authorJames F. Reid
Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
IFOM, FIRC Institute of Molecular Oncology, Milan, Italy
Search for more papers by this authorLaura Zannini
Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
Search for more papers by this authorManuela Gariboldi
Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
IFOM, FIRC Institute of Molecular Oncology, Milan, Italy
Search for more papers by this authorLars Kjeldsen
Department of Hematology, National University Hospital, Copenhagen, Denmark
Search for more papers by this authorCorresponding Author
Marco A. Pierotti
Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
IFOM, FIRC Institute of Molecular Oncology, Milan, Italy
Department of Experimental Oncology, Istituto Nazionale Tumori, Via G Venezian 1, 20133 Milan, ItalySearch for more papers by this authorCorresponding Author
Domenico Delia
Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
Department of Experimental Oncology, Istituto Nazionale Tumori, Via G Venezian 1, 20133 Milan, ItalySearch for more papers by this authorAbstract
N-(4-Hydroxyphenyl)retinamide (4-HPR) is a nonclassical retinoid with cancer preventive effects in vivo and antiproliferative and apoptotic activities in vitro. Examining the transcriptional profile of human breast cancer cell lines, MCF7 and T47D, treated with 4-HPR, we identified the lipocalin member LCN2 (NGAL or 24p3) as a gene, markedly induced by the retinoid. Because of its presumed function in apoptosis, LCN2 was examined more thoroughly in response to 4-HPR. Like mRNA, the expression of LCN2 protein in MCF7 and T47D cells was highly induced in a time-dependent manner by 4-HPR, but not by its inactive metabolite 4-MPR and, to some extent, this event was linked to the free radicals normally generated by 4-HPR. All-trans retinoic acid also induced LCN2 protein, particularly in T47D cells. Ectopic LCN2 compromised cell viability, and the few MCF7 clones that survived LCN2 overexpression were less sensitive than do mock cells to 4HPR, indicating that selective pressure for survival to LCN2 confers cross-resistance to 4-HPR. Significantly, ablation of LCN2 induction by siRNA did not modify the response to 4-HPR, implying that LCN2 is not critical for apoptosis by 4-HPR. Our results indicate that 4-HPR markedly induces LCN2 expression, but this event may not represent an apoptotic response. © 2006 Wiley-Liss, Inc.
References
- 1 Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002; 41: 41–55. Review.
- 2 Sporn MB, Suh N. Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer 2002; 2: 537–43.
- 3 Delia D, Aiello A, Lombardi L, Pelicci PG, Grignani F, Grignani F, Formelli F, Menard S, Costa A, Veronesi U. N-(4-Hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993; 53: 6036–41.
- 4 Delia D, Aiello A, Formelli F, Fontanella E, Costa A, Miyashita T, Reed JC, Pierotti MA. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2. Blood 1995; 85: 359–67.
- 5 Formelli F, Barua AB, Olson JA. Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl β-glucuronide. FASEB J 1996; 10: 1014–24.
- 6
Fanjul AN,
Delia D,
Pierotti MA,
Rideout D,
Yu JQ,
Pfahl M,
Qiu J.
4-(Hydroxyphenyl) retinamide is a highly selective activator of retinoid receptors.
J Biol Chem
1996;
27:
22441–6.
10.1074/jbc.271.37.22441 Google Scholar
- 7 Panigone S, Debernardi S, Taya Y, Fontanella E, Airoldi R. pRb and Cdk regulation by N-(4-hydroxyphenyl) retinamide. Oncogene 2000; 19: 4035–41.
- 8 Dragnev KH, Pitha-Rowe I, Ma Y, Petty WJ, Sekula D, Murphy B, Rendi M, Suh N, Desai NB, Sporn MB, Freemantle SJ, Dmitrovsky E. Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. Clin Cancer Res 2004; 10: 2570–7.
- 9 Delia D, Aiello A, Meroni L, Nicolini M, Reed JC, Pierotti MA. Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Carcinogenesis 1997; 18: 943–8.
- 10 Panigone S, Bergomas R, Fontanella E, Prinetti A, Sandhoff K, Grabowski GA, Delia D. Up-regulation of prosaposin by the retinoid HPR and its effect on ceramide production and integrin receptors. FASEB J 2001; 15: 1475–7.
- 11 Lovat PE, Di Sano F, Corazzari M, Fazi B, Donnorso RP, Pearson AD, Hall AG, Redfern CP, Piacentini M. Gangliosides link the acidic sphingomyelinase-mediated induction of ceramide to 12-lipoxygenase-dependent apoptosis of neuroblastoma in response to fenretinide. J Natl Cancer Inst 2004; 96: 1288–99.
- 12 Moon RC, Thompson HJ, Becci PJ, Grubbs CJ, Gander RJ, Newton DL, Smith JM, Phillips SL, Henderson WR, Mullen LT, Brown CC, Sporn MB. N-4-(Hydroxyphenyl)retinamide, a new retinoid for the prevention of breast cancer in the rat. Cancer Res 1979; 39: 1339–46.
- 13 Ratko TA, Detrisac CJ, Dinger NM, Thomas CF, Kelloff GJ, Moon RC. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of primary mammary cancer in female rats. Cancer Res 1989; 49: 4472–86.
- 14 Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF, Sigman CC. Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Res 1992; 12: 1147–53.
- 15 Cope MB, Steele VE, Lubet RA, Eto I, Juliana MM, Hill DL, Grubbs CJ. Efficacy of 9-cis-retinoic acid and N-(4-hydroxyphenyl) retinamide alone and in combination in mammary cancer prevention. Oncol Rep 2004; 11: 465–9.
- 16 Ferrari N, Morini M, Pfeffer U, Minghelli S, Noonan DM, Albini A. Inhibition of Kaposi's sarcoma in vivo by fenretinide. Clin Cancer Res 2003; 9: 6020–9.
- 17 Gopal AK, Pagel JM, Hedin N, Press OW. Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. Blood 2004; 103: 3516–20.
- 18 Simeone AM, Deng CX, Kelloff GJ, Steele VE, Johnson MM, Tari AM. N-(4-Hydroxyphenyl) retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells. Carcinogenesis 2005; 26: 1000–7.
- 19 Malone W, Perloff M, Crowell J, Sigman C, Higley H. Fenretinide: a prototype cancer prevention drug. Expert Opin Investig Drugs 2003; 12: 1829–42.
- 20 Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A, Camerini T, Del Turco MR, Di Mauro MG, Muraca MG, Del Vecchio M et al. Randomised trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999; 91: 1847–56.
- 21 Follen M, Atkinson EN, Schottenfeld D, Malpica A, West L, Lippman S, Zou C, Hittelman WN, Lotan R, Hong WK. A randomised clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. Clin Cancer Res 2001; 7: 3356–65.
- 22 Ferrari N, Pfeffer U, Dell'Eva R, Ambrosini C, Noonan DM, Albini A. The transforming growth factor-β family members bone morphogenetic protein-2 and macrophage inhibitory cytokine1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide. Clin Cancer Res 2005; 11: 4610–19.
- 23 Christov KT, Shilkaitis AL, Kim ES, Steele VE, Lubet RA. Chemopreventive agents induce a senescence-like phenotype in rat mammary tumours. Eur J Cancer 2003; 39: 230–9.
- 24 Flower DR, North AC, Sansom CE. The lipocalin protein family: structural and sequence overview. Biochim Biophys Acta 2000; 1482: 9–24.
- 25 Bratt T. Lipocalins and cancer. Biochim Biophys Acta 2000; 1482: 318–26.
- 26 Devireddy LR, Teodoro JG, Richard FA, Green MR. Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science 2001; 293: 829–34.
- 27 Tong Z, Wu X, Kehrer JP. Increased expression of the lipocalin 24p3 as an apoptotic mechanism for MK886. Biochem J 2003; 372: 203–10.
- 28 De Cecco L, Marchionni L, Gariboldi M, Reid JF, Lagonigro MS, Caramuta S, Ferrario C, Bussani E, Mezzanzanica D, Turatti F, Delia D, Daidone MG et al. Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene 2004; 23: 8171–83.
- 29 Reid JF, Lusa L, De Cecco L, Coradini D, Veneroni S, Daidone MG, Gariboldi M, Pierotti MA. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst 2005; 97: 927–30.
- 30 Kjeldsen L, Koch C, Arnljots K, Borregaard N. Characterization of two ELISAs for NGAL, a newly described lipocalin in human neutrophils. J Immunol Methods 1996; 198: 155–64.
- 31 Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25: 25–9.
- 32 Hanai J, Mammoto T, Seth P, Mori K, Karumanchi SA, Barasch J, Sukhatme VP. Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem 2005; 280: 13641–7.
- 33 Kamezaki K, Shimoda K, Numata A, Aoki K, Kato K, Takase K, Nakajima H, Ihara K, Haro T, Ishikawa F, Imamura R, Miyamoto T et al. The lipocalin 24p3, which is an essential molecule in IL-3 withdrawal-induced apoptosis, is not involved in the G-CSF withdrawal-induced apoptosis. Eur J Haematol 2003; 71: 412–7.
- 34 Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004; 432: 917–21.
- 35 Schlehuber S, Skerra A. Lipocalins in drug discovery: from natural ligand-binding proteins to anticalins. Drug Discov Today 2005; 10: 23–33.
- 36 Oridate N, Suzuki S, Higuchi M, Mitchell MF, Hong WK, Lotan R. Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 1997; 89: 1191–8.
- 37 Sun SY, Li W, Yue P, Lippman SM, Hong WK, Lotan R. Mediation of N-(4-hydoxyphenyl) retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res 1999; 59: 2493–8.
- 38 Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003; 22: 7305–15.
- 39 Hail N,Jr, Lotan R. Mitochondrial respiration is uniquely associated with the prooxidant and apoptotic effects of N-(4-hydroxyphenyl)retinamide. J Biol Chem 2001; 276: 45614–21.
- 40 Cuello M, Coats AO, Darko I, Ettenberg SA, Gardner GJ, Nau MM, Liu JR, Birrer MJ, Lipkowitz S. N-(4-Hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines. Cell Death Differ 2004; 11: 527–41.
- 41 Gopal AK, Pagel JM, Hedin N, Press OW. Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. Blood 2004; 103: 3516–20.
- 42 Sun SY, Hail N,Jr, Lotan R. Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst 2004; 96: 662–72.
- 43 Persengiev SP, Devireddy LR, Green MR. Inhibition of apoptosis by ATFx: a novel role for a member of the ATF/CREB family of mammalian bZIP transcription factors. Genes Dev 2002; 16: 1806–14.
- 44 Ryon J, Bendickson L, Nilsen-Hamilton M. High expression in involuting reproductive tissues of uterocalin/24p3, a lipocalin and acute phase protein. Biochem J 2002; 367: 271–7.
- 45 Bong JJ, Seol MB, Kim HH, Han O, Back K, Baik M. The 24p3 gene is induced during involution of the mammary gland and induces apoptosis of mammary epithelial cells. Mol Cells 2004; 17: 29–34.
- 46 Devireddy LR, Gazin C, Zhu X, Green MR. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 2005; 123: 1293–305.